IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. - Wikidata - wikimedia - TriplyDB

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.

http://www.wikidata.org/entity/Q35037290

about

Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: implications for the prostate tumor microenvironment Glucocorticoids and prostate cancer treatment: friend or foe?-174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race.Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.The role of interleukin-6 in malignant mesothelioma Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells The PCa Tumor Microenvironment.SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma.Arsenic-transformed malignant prostate epithelia can convert noncontiguous normal stem cells into an oncogenic phenotype.Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.A distinct role for interleukin-6 as a major mediator of cellular adjustment to an altered culture condition.Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Immune mediators in the tumor microenvironment of prostate cancer.Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Proinflammatory cytokine interleukin-6 in prostate carcinogenesis Areca nut exposure increases secretion of tumor-promoting cytokines in gingival fibroblasts that trigger DNA damage in oral keratinocytes.lnflammation-induced epigenetic switches in cancer.Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis.Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?Ninjurin1 suppresses metastatic property of lung cancer cells through inhibition of interleukin 6 signaling pathway.The interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the lacrimal gland.Hepcidin regulation in prostate and its disruption in prostate cancer.Senescent stroma promotes prostate cancer progression: the role of miR-210.Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation.Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?Associations between fruit, vegetable and legume intakes and prostate cancer risk: results from the prospective Supplémentation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) cohort.

P2860

Q28304032-221A72A3-32C0-435A-8366-ACBFAF0AEB9D Q33621387-DC762D4C-F100-40C8-B2D5-8252EDE173A6 Q33684259-C789605A-A90D-4C4B-A4B9-7BCE418B75DA Q34460302-3EF831B4-4593-4E9D-9A91-1E673C37FEAF Q34559139-0B64E2D7-2F57-43D1-8A4C-79200FC1EAE9 Q34780162-25BB3D3F-B936-4488-BE9F-0703D8EA66F3 Q34971771-7ED117BA-C784-41A6-95CE-97E811F65DED Q35200628-B3417183-7B3B-4B0B-974A-880224183190 Q35356072-6E085D24-49CB-4127-88CC-DC4CC413C569 Q35579329-33065E09-D8A7-4DAE-979D-0F34E661CA81 Q35603143-F13503B8-CB9A-47BF-9596-50285F42A318 Q35983468-9FFBD1F4-8489-4A49-B24B-9A6CCB023FBB Q36010641-A9C79540-4622-47C7-BCDB-3278727EA18F Q36064793-F1A7341C-FE3A-4CDC-ACB8-755B1BA60AD8 Q36368188-B4D2C311-B29A-4CB5-996F-AAF58B5346ED Q36685345-0B1128F2-39A7-437B-A466-88C0CFA64C80 Q36799733-12492B11-53DE-4009-8EF1-683BDC353344 Q37064043-FBDE50CD-3A0B-4C84-862D-47B4648A92DA Q37200413-2C00AC48-8344-4FBE-A259-836FFC781691 Q37239331-EEB3A4AC-F79A-451C-8F08-1504435A5FEA Q37619770-2F80A82F-87C7-44FB-A1D8-EB7381F8FC02 Q37629548-9FC75D27-0048-4DBD-AEB3-732CF0689F8F Q37701076-1B7B3733-DA1F-4DBC-88A0-718A24B888AE Q38177688-E181A2AE-9752-4321-83B7-D7D837C0F123 Q38177689-7912529E-715A-4183-9DEE-908CC0024D17 Q38265575-1DC48D15-CE04-4281-957D-C834C4148897 Q38276312-2E07557C-44F5-445C-B701-F6E99A9097AD Q38591056-F3CFBDFE-0D61-478F-9521-3FF587C0D72E Q38627406-D90922C1-9434-42F3-AAFA-CB765E8F9A6B Q38734599-506A67B4-C8D3-49E1-A89B-A7B61334B014 Q38780033-3B247B8C-4DFA-4790-B8D7-CACAD63176AD Q38799164-19DFF188-93B6-4090-B245-285AAB619B9C Q38855103-D61893E1-6935-4829-910C-9C0D1D741353 Q38889135-DBE37381-B902-4C22-B179-24C7276767D7 Q38968807-42576190-B6F3-4215-808C-265132B54AD8 Q39024619-811A8346-077C-4D4E-8952-467463EC1543 Q39268054-9B40B223-15ED-44C2-A01D-D65EC2C8A209 Q39340075-9B3B62B8-53BE-4D22-A06D-1748768E8876 Q40707324-EA4C0200-DB96-422C-BA6D-FD4EEA9D12B1 Q40867947-D25448AB-C878-4275-876B-C1E0CA106706

P2860

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.

http://www.wikidata.org/entity/Q35037290

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@ast

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@en

type

label

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@ast

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@en

prefLabel

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@ast

IL-6 promotes prostate tumorig ...... ne cross-activation of IGF-IR.

@en

P1433

Q35037290-BC1E5B6F-100C-41F5-8B7F-D23A334353D5

P1476

Q35037290-7A841A95-1A61-4E53-9A66-55A3E823BD20

P2093

Q35037290-18BA589F-15BE-48F2-B24D-6FAC79DF2880

Q35037290-20EE0683-CF66-440A-8D73-455FB6D6F425

Q35037290-250ED8E1-F783-40CB-BDDD-010A17FCCA56

Q35037290-9DF70E9A-279D-497D-B6D8-4D34E4389F6A

Q35037290-A5FF8D07-0F8A-4E35-9BE0-42F3272FD3D2

Q35037290-B441D870-631F-4D52-A8F2-465958A1451F

Q35037290-DE06EAC4-9F44-4E48-95B2-D9E626FD0073

P2860

Q35037290-006C58F1-708D-4633-9587-2B4F69CA080A

Q35037290-03305A37-5291-4045-AD9B-B1A86F13EB05

Q35037290-1132F88E-676E-40AF-80BB-D52DA5C72E17

Q35037290-148EC154-7C1F-491F-96CA-B7114D0A61E0

Q35037290-14F947DC-0E55-4FF8-BDD4-EC628C0415B0

Q35037290-1D649B63-C99D-4813-8701-EE17E094B18F

Q35037290-1F017D1E-CAA9-49F9-B971-3DFB93C5BECC

Q35037290-31F74266-0127-4A0A-A6DF-A7CC8C290663

Q35037290-387ED0AF-07A8-4078-BE48-46DFE2C91A1B

Q35037290-3966BC88-1DC9-4D24-959F-E9DC8559C01D

P2888

Q35037290-69E69BF6-0C9A-47C0-B90A-C885C8C6C02D

P304

Q35037290-301DECB1-3287-454D-AC37-EA6D28D75F54

P31

Q35037290-DEFA978E-CD50-40CD-A898-05E862705F07

P356

Q35037290-31FE053B-3678-4E32-B859-FE36B9214F67

P407

Q35037290-4E80EADB-E995-4B0A-95DD-BFA387127ED5

P433

Q35037290-F9A129B0-FFD3-41AB-9BA0-78DB3043DD5B

P478

Q35037290-216B1735-F62D-439D-AC72-BEF9AA655987

P50

Q35037290-4413A01F-26A9-4551-9AE0-960EF925FF3B

Q35037290-5651F2FE-FA75-4AA5-9CE9-66620608E00D

P577

Q35037290-2A3389EF-28F2-427A-89E5-0B541BF3791C

P5875

Q35037290-37CC38A8-ADD6-4418-993D-32E343D6E276

P698

Q35037290-417A15F5-E3C5-4C54-9E5D-E6AC552E8CC5

P932

Q35037290-7E06528B-8C40-4240-B898-67223A9A1EBA

P356

P1433

P1476

IL-6 promotes prostate tumorig ...... ine cross-activation of IGF-IR

@en

P2093

A Rojas

http://www.w3.org/2001/XMLSchema#string

G Liu

http://www.w3.org/2001/XMLSchema#string

I Coleman

http://www.w3.org/2001/XMLSchema#string

J D Wu

http://www.w3.org/2001/XMLSchema#string

P B Fisher

http://www.w3.org/2001/XMLSchema#string

P S Nelson

http://www.w3.org/2001/XMLSchema#string

S R Plymate

http://www.w3.org/2001/XMLSchema#string

P2860

Significance analysis of microarrays applied to the ionizing radiation response

Epithelial-mesenchymal transitions in tumour progression

Epithelial-mesenchymal transitions in development and disease

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

Ras oncogenes: split personalities

Obesity and prostate cancer: making sense out of apparently conflicting data.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis.

P2888

P304

2345-2355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2010.605

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49777596

http://www.w3.org/2001/XMLSchema#string

P698

21258401

http://www.w3.org/2001/XMLSchema#string

P932

3112005

http://www.w3.org/2001/XMLSchema#string